Drew Janice Suzann 4

What Happened

• Drew Janice Suzann, Chief of Development Operations at Evommune (EVMN), exercised stock options to acquire a total of 20,000 shares (3,839 shares @ $3.84; 16,161 shares @ $2.99) and immediately sold those 20,000 shares in the open market.
• The exercises required cash outlays of $14,742 and $48,321 (total exercise cost $63,063). The sale was for a weighted-average price of $22.63 per share, generating gross proceeds of $452,600 (net proceeds ≈ $389,537 before fees/taxes).
• This is routine insider selling following option exercises rather than a fresh cash purchase (i.e., not a direct bullish purchase signal).

Key Details

• Transaction date: June 22, 2026; Form filed: June 24, 2026 (timely).
• Option exercises: 3,839 shares @ $3.84 and 16,161 shares @ $2.99 (transaction code M).
• Sale: 20,000 shares sold in open market @ weighted avg $22.63 for $452,600 (transaction code S). Reported sale prices ranged from $22.50 to $23.12; the filer can provide a breakdown on request (Footnote F2).
• Plan: Sales were made pursuant to a Rule 10b5-1 trading plan adopted March 9, 2026 (Footnote F1).
• Vesting info: The option award is subject to time-based vesting (1/4 after 1 year, then monthly over 36 months) per Footnote F3.
• Shares owned after the transactions: not specified in the provided filing excerpt.

Context

• This was effectively an exercise-and-sell (common cashless-style outcome): the insider exercised vested options, paid the exercise prices, and sold the resulting shares under a pre-established 10b5-1 plan.
• Such transactions are common for insiders needing liquidity or to cover exercise/tax costs; they are factual disclosures and do not by themselves indicate company performance.